Medicine
Xuriden 951 mg/g granules
Xuriden 951 mg/g granules is a prescription medicine containing Uridine triacetate for oral use, marketed by BTG International, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at controlled room temperature, 25°C (77°F), excursions permitted to 15°…
Key facts
- Active ingredient (INN)
- Uridine triacetate
- Brand
- Xuriden
- Strength
- 951 mg/g
- Dosage form
- Granules
- Route
- Oral
- Packs
- 30 packets
- Marketing authorisation holder
- BTG International
- Manufacturer
- BTG International
- Origin register
- US FDA, United States
- Storage
- Store at controlled room temperature, 25°C (77°F), excursions permitted to 15° to 30°C (59° to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A16AX13 Uridine triacetate
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 31 May 2024
- Identifiers
- RxCUI 1665467, 1665473DailyMed set ID 88ca4d2b-3905-474b-9fd6-c81474f2fb4bNDC 50633-330Application NDA208169
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 packet in 1 carton / 2 g in 1 packet | 50633-330-30 | BTG International | 31 May 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 4 September 2015 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Uridine triacetate 951 mg/g granules.
Clinical summary
Uridine triacetate is a pyrimidine analog indicated in adult and pediatric patients for the treatment of hereditary orotic aciduria. It is available as granules for oral use. MedsAcross supplies Uridine triacetate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Uridine triacetateFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- XURIDEN prescribing information (BTG International) · U.S. National Library of Medicine, DailyMed
Need Xuriden 951 mg/g granules for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.